mardi 28 juin 2016

Onco Actu du 28 juin 2016

2. Etiologie

Invoking cancer and stress in the same breath is not the same as blaming the victim [The Guardian]

5.2.1 Pharma - Partenariats

Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor [Novartis]

Novartis and Xencor enter into bispecific antibody agreement [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

The Zerhouni rule: “Every company that acquires a platform company kills it.” [ENDPOINTS]

5.2.3 Pharma - économie

UK pharma trade group on Brexit: ‘There’s a potentially negative story here’ [STAT]

The Supreme Court decision that’s shaking up biotech [STAT]

Pfizer to invest $350 million in China biotech hub, first in Asia [Reuters]

5.3 Traitements - FDA, EMA,...

What six former FDA commissioners advise their successor [STAT]

5.3.4 Traitements - AMM (FDA, EMA)

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer [BMS]

5.5 ASCO

Gastrointestinal Cancers: Immediate Impact of 2016 ASCO Presentations on Clinical Practice [The OBR Blog]

6. Lutte contre les cancers

Well: Putting Breast Cancer on a Diet [NY Times]

6.10 Politiques

Martin McKee: Brexit and health—the confusion grows [BMJ Blogs]

6.6 Publications

Cancer researcher committed misconduct “recklessly,” says investigation [Retraction Watch]

Investigation raises questions about top cancer researcher’s work [Retraction Watch]